Effect of selective serotonin reuptake inhibitors on bone mineral density: a systematic review and meta-analysis

  • C. Zhou
  • L. Fang
  • Y. Chen
  • J. Zhong
  • H. Wang
  • P. Xie
Review

Abstract

Our work is the first systematic meta-analysis to investigate the effect of selective serotonin reuptake inhibitor (SSRI) medication on bone mineral density. Through meta-analyzed 11 studies, our findings suggested that compared with nonusers, use of SSRIs was significantly associated with lumbar spine BMD reduction, particularly for old people. The use of selective serotonin reuptake inhibitors (SSRIs) has already been associated with bone mass loss. Their effects on bone mineral density (BMD) for the different bone sections have, however, thus been inconsistent. Here, we aim to assess the effects of SSRIs on BMD using a meta-analysis. We searched PubMed, Scopus, ISI Web of Knowledge, the Cochrane Library, and PsycINFO for all English-written studies investigating the effects of SSRIs on BMD and published before November 2017. BMD was compared between non-SSRI users and SSRI users using a random-effect model with standardized mean differences (SMD) and 95% confidence intervals (CIs). Furthermore, subgroup analyses were performed based on study design, age, and sex in order to find the origins of high heterogeneity. Eleven studies met the inclusion criteria and were used for the meta-analysis. Our study demonstrated that the use of SSRIs was significantly associated with lower BMD values (SMD − 0.40; 95% CI − 0.79 to 0.00; p = 0.05) and BMD Z-scores (SMD − 0.28; 95% CI − 0.50 to − 0.05; p = 0.02) of the lumbar spine, but not of the total hip and femoral neck. In addition, SSRI use was associated with a greater bone loss in older people. SSRI use is a risk factor of lower BMD of the lumbar spine, especially for older people. Future studies into the relationship between SSRI use and bone metabolism and bone mass need to be conducted with larger sample sizes for both men and women at different bone sites.

Keywords

Antidepressant Bone mineral density Meta-analysis Selective serotonin reuptake inhibitors 

Notes

Acknowledgements

The work was supported by The National Key Research and Development Program of China (Grant No. 2017YFA0505700), National Natural Science Foundation of China (Grant No. 81701361), and China Postdoctoral Science Foundation funded project (Project No. 2017M612924).

Compliance with ethical standards

Conflicts of interest

None.

Supplementary material

198_2018_4413_MOESM1_ESM.doc (63 kb)
Table S1 PRISMA 2009 checklist (DOC 63 kb).
198_2018_4413_MOESM2_ESM.xlsx (12 kb)
Table S2 BMD value, BMD T-score and BMD Z-score of 11 included studies (XLSX 12 kb).

References

  1. 1.
    Ferguson JM (2001) SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 3(1):22–27.  https://doi.org/10.4088/PCC.v03n0105 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Fernandes BS, Hodge JM, Pasco JA, Berk M, Williams LJ (2016) Effects of depression and serotonergic antidepressants on bone: mechanisms and implications for the treatment of depression. Drugs Aging 33(1):21–25.  https://doi.org/10.1007/s40266-015-0323-4 CrossRefPubMedGoogle Scholar
  3. 3.
    Schwan S, Hallberg P (2009) SSRIs, bone mineral density, and risk of fractures—a review. Eur Neuropsychopharmacol 19(10):683–692.  https://doi.org/10.1016/j.euroneuro.2009.05.001 CrossRefPubMedGoogle Scholar
  4. 4.
    Eom CS, Lee HK, Ye S, Park SM, Cho KH (2012) Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis. J Bone Miner Res 27(5):1186–1195.  https://doi.org/10.1002/jbmr.1554 CrossRefPubMedGoogle Scholar
  5. 5.
    Wu Q, Bencaz AF, Hentz JG, Crowell MD (2012) Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case–control studies. Osteoporos Int 23(1):365–375.  https://doi.org/10.1007/s00198-011-1778-8 CrossRefPubMedGoogle Scholar
  6. 6.
    Diem SJ, Blackwell TL, Stone KL, Yaffe K, Haney EM, Bliziotes MM, Ensrud KE (2007) Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 167(12):1240–1245.  https://doi.org/10.1001/archinte.167.12.1240 CrossRefPubMedGoogle Scholar
  7. 7.
    Haney EM, Chan BKS, Diem SJ et al (2007) Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 167(12):1246–1251.  https://doi.org/10.1001/archinte.167.12.1246 CrossRefPubMedGoogle Scholar
  8. 8.
    Richards JB, Papaioannou A, Adachi JD et al (2007) Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 167(2):188–194CrossRefPubMedGoogle Scholar
  9. 9.
    Ham AC, Aarts N, Noordam R et al (2017) Use of selective serotonin reuptake inhibitors and bone mineral density change: a population-based longitudinal study in middle-aged and elderly individuals. J Clin Psychopharmacol 37(5):524–530.  https://doi.org/10.1097/JCP.0000000000000756 CrossRefPubMedGoogle Scholar
  10. 10.
    Saraykar S, John V, Cao B, Hnatow M, Ambrose CG, Rianon N (2017) Association of selective serotonin reuptake inhibitors and bone mineral density in elderly women. J Clin Densitom.  https://doi.org/10.1016/j.jocd.2017.05.016
  11. 11.
    Felson DT, Zhang Y, Hannan MT, Anderson JJ (1993) Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J Bone Miner Res 8(5):567–573.  https://doi.org/10.1002/jbmr.5650080507 CrossRefPubMedGoogle Scholar
  12. 12.
    Riggs BL, Wahner HW, Dunn WL, Mazess RB, Offord KP, Melton LJ 3rd (1981) Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest 67(2):328–335.  https://doi.org/10.1172/JCI110039 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Lim S, Joung H, Shin CS et al (2004) Body composition changes with age have gender-specific impacts on bone mineral density. Bone 35(3):792–798CrossRefPubMedGoogle Scholar
  14. 14.
    Courteix D, Lespessailles E, Peres SL, Obert P, Germain P, Benhamou CL (1998) Effect of physical training on bone mineral density in prepubertal girls: a comparative study between impact-loading and non-impact-loading sports. Osteoporos Int 8(2):152–158.  https://doi.org/10.1007/BF02672512 CrossRefPubMedGoogle Scholar
  15. 15.
    Chau K, Atkinson SA, Taylor VH (2012) Are selective serotonin reuptake inhibitors a secondary cause of low bone density? J Osteoporos 323061:1–7.  https://doi.org/10.1155/2012/323061 CrossRefGoogle Scholar
  16. 16.
    Calarge CA, Mills JA, Janz KF, Burns TL, Schlechte JA, Coryell WH, Zemel BS (2017) The effect of depression, generalized anxiety, and selective serotonin reuptake inhibitors on change in bone metabolism in adolescents and emerging adults. J Bone Miner Res 32(12):2367–2374.  https://doi.org/10.1002/jbmr.3238 CrossRefPubMedGoogle Scholar
  17. 17.
    Winterhalder L, Eser P, Widmer J, Villiger PM, Aeberli D (2012) Changes in volumetric BMD of radius and tibia upon antidepressant drug administration in young depressive patients. J Musculoskelet Neuronal Interact 12(4):224–229PubMedGoogle Scholar
  18. 18.
    Calarge CA, Zimmerman B, Xie D, Kuperman S, Schlechte JA (2010) A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry 71(3):338.  https://doi.org/10.4088/JCP.08m04595gre. CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    An KY, Shin WJ, Lee KJ (2013) The necessity of bone densitometry for patients taking selective serotonin reuptake inhibitors. J Bone Metab 20(2):95–98.  https://doi.org/10.11005/jbm.2013.20.2.95 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Calarge CA, Burns TL, Schlechte JA, Zemel BS (2015) Longitudinal examination of the skeletal effects of selective serotonin reuptake inhibitors and risperidone in boys. J Clin Psychiatry 76(5):607–613.  https://doi.org/10.4088/JCP.14m09195 CrossRefPubMedGoogle Scholar
  21. 21.
    Bolton JM, Morin SN, Majumdar SR, Sareen J, Lix LM, Johansson H, Odén A, McCloskey EV, Kanis JA, Leslie WD (2017) Association of mental disorders and related medication use with Risk for major osteoporotic fractures. JAMA Psychiatry 74(6):641–648.  https://doi.org/10.1001/jamapsychiatry.2017.0449 CrossRefPubMedGoogle Scholar
  22. 22.
    Seifert CF, Wiltrout TR (2013) Calcaneal bone mineral density in young adults prescribed selective serotonin reuptake inhibitors. Clin Ther 35(9):1412–1417.  https://doi.org/10.1016/j.clinthera.2013.07.423 CrossRefPubMedGoogle Scholar
  23. 23.
    Rauma PH, Pasco JA, Berk M, Stuart AL, Koivumaa-Honkanen H, Honkanen RJ, Hodge JM, Williams LJ (2015) The association between major depressive disorder, use of antidepressants and bone mineral density (BMD) in men. J Musculoskelet Neuronal Interact 15(2):177–185PubMedPubMedCentralGoogle Scholar
  24. 24.
    Moura C, Bernatsky S, Abrahamowicz M et al (2014) Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS). Osteoporos Int 25(5):1473–1481.  https://doi.org/10.1007/s00198-014-2649-x. CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Bolton JM, Targownik LE, Leung S, Sareen J, Leslie WD (2011) Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women. J Clin Psychopharmacol 31(1):56–60.  https://doi.org/10.1097/JCP.0b013e3182075587 CrossRefPubMedGoogle Scholar
  26. 26.
    Cauley JA, Fullman RL, Stone KL, Zmuda JM, Bauer DC, Barrett-Connor E, Ensrud K, Lau EMC, Orwoll ES, For the Mr. OS Research Group (2005) Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int 16(12):1525–1537.  https://doi.org/10.1007/s00198-005-1866-8 CrossRefPubMedGoogle Scholar
  27. 27.
    Couturier J, Sy A, Johnson N, Findlay S (2013) Bone mineral density in adolescents with eating disorders exposed to selective serotonin reuptake inhibitors. Eat Disord 21(3):238–248.  https://doi.org/10.1080/10640266.2013.779183 CrossRefPubMedGoogle Scholar
  28. 28.
    Feuer AJ, Demmer RT, Thai A, Vogiatzi MG (2015) Use of selective serotonin reuptake inhibitors and bone mass in adolescents: an NHANES study. Bone 78:28–33.  https://doi.org/10.1016/j.bone.2015.04.042 CrossRefPubMedGoogle Scholar
  29. 29.
    Diem SJ, Ruppert K, Cauley JA et al (2013) Rates of bone loss among women initiating antidepressant medication use in midlife. J Clin Endocrinol Metab 98(11):4355–4363.  https://doi.org/10.1210/jc.2013-1971. CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Ak E, Bulut SD, Bulut S, Akdağ HA, Öter GB, Kaya H, Kaya OB, Şengül CB, Kısa C (2015) Evaluation of the effect of selective serotonin reuptake inhibitors on bone mineral density: an observational cross-sectional study. Osteoporos Int 26(1):273–279.  https://doi.org/10.1007/s00198-014-2859-2 CrossRefPubMedGoogle Scholar
  31. 31.
    Diem SJ, Blackwell TL, Stone KL et al (2011) Use of antidepressant medications and risk of fracture in older women. Calcif Tissue Int 88(6):476–484.  https://doi.org/10.1007/s00223-011-9481-5 CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Misra M, Le Clair M, Mendes N et al (2010) Use of SSRIs may impact bone density in adolescent and young women with anorexia nervosa. CNS Spectr 5(9):579–586CrossRefGoogle Scholar
  33. 33.
    Rauma PH, Honkanen RJ, Williams LJ, Tuppurainen MT, Kröger HP, Koivumaa-Honkanen H (2016) Effects of antidepressants on postmenopausal bone loss—a 5-year longitudinal study from the OSTPRE cohort. Bone 89:25–31.  https://doi.org/10.1016/j.bone.2016.05.003 CrossRefPubMedGoogle Scholar
  34. 34.
    Williams LJ, Henry MJ, Berk M, Dodd S, Jacka FN, Kotowicz MA, Nicholson GC, Pasco JA (2008) Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int Clin Psychopharmacol 23(2):84–87.  https://doi.org/10.1097/YIC.0b013e3282f2b3bb CrossRefPubMedGoogle Scholar
  35. 35.
    Bliziotes M (2010) Update in serotonin and bone. J Clin Endocrinol Metab 95(9):4124–4132.  https://doi.org/10.1210/jc.2010-0861 CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Hodge JM, Wang Y, Berk M, Collier FM, Fernandes TJ, Constable MJ, Pasco JA, Dodd S, Nicholson GC, Kennedy RL, Williams LJ (2013) Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function. Biol Psychiatry 74(1):32–39.  https://doi.org/10.1016/j.biopsych.2012.11.003 CrossRefPubMedGoogle Scholar
  37. 37.
    Gustafsson BI, Thommesen L, Stunes AK et al (2006) Serotonin and fluoxetine modulate bone cell function in vitro. J Cell Biochem 98(1):139–151CrossRefPubMedGoogle Scholar
  38. 38.
    Warden SJ, Robling AG, Sanders MS, Bliziotes MM, Turner CH (2005) Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 146(2):685–693.  https://doi.org/10.1210/en.2004-1259 CrossRefPubMedGoogle Scholar
  39. 39.
    Warden SJ, Bliziotes MM, Wiren KM, Eshleman AJ, Turner CH (2005) Neural regulation of bone and the skeletal effects of serotonin (5-hydroxytryptamine). Mol Cell Endocrinol 42(1):1–9CrossRefGoogle Scholar
  40. 40.
    Ortuño MJ, Robinson ST, Subramanyam P, Paone R, Huang Y, Guo XE, Colecraft HM, Mann JJ, Ducy P (2016) Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local anti-resorptive effect. Nat Med 22(10):1170–1179.  https://doi.org/10.1038/nm.4166 CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Ho SC, Chan SG, Yip YB, Chan CS, Woo JL, Sham A (2008) Change in bone mineral density and its determinants in pre-and perimenopausal Chinese women: the Hong Kong perimenopausal women osteoporosis study. Osteoporos Int 19(12):1785–1796.  https://doi.org/10.1007/s00198-008-0614-2 CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2018

Authors and Affiliations

  • C. Zhou
    • 1
    • 2
    • 3
  • L. Fang
    • 1
  • Y. Chen
    • 1
  • J. Zhong
    • 1
  • H. Wang
    • 2
    • 3
  • P. Xie
    • 1
    • 2
    • 3
    • 4
  1. 1.Department of NeurologyYongchuan Hospital of Chongqing Medical UniversityChongqingChina
  2. 2.Institute of NeuroscienceChongqing Medical UniversityChongqingChina
  3. 3.Chongqing Key Laboratory of NeurobiologyChongqing Medical UniversityChongqingChina
  4. 4.Department of NeurologyThe First Affiliated Hospital of Chongqing Medical UniversityChongqingChina

Personalised recommendations